Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 9/20 | 0.39 |
| ▸ | MAOA | P21397 | 8/20 | 0.39 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15922645 | 1.00 | HSD11B1 (0.49) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1557921 | 0.77 | HSD11B1 (0.43) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1353430 | 0.77 | HSD11B1 (0.52) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6896759 | 0.74 | HSD11B1 (0.53) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL26828423 | 0.74 | HSD11B1 (0.49) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6897711 | 0.74 | HSD11B1 (0.62) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4846118 | 0.74 | GRIN2D (0.47) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL6894594 | 0.72 | HSD11B1 (0.60) | HSD11B1MAOBMAOA | |
| SCHEMBL6680933 | 0.71 | HSD11B1 (0.58) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24549947 | 0.70 | HSD11B1 (0.41) | HSD11B1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023210472-A1 | RESIST COMPOSITION AND RESIST PATTERN FORMING METHOD | 東京応化工業株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-9840465-B2 | Antiviral compounds | UNIV BRIGHAM YOUNG (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840465-B2 | Antiviral compounds | UNIV BRIGHAM YOUNG (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150368196-A1 | ANTIVIRAL COMPOUNDS | UNIV BRIGHAM YOUNG (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368196-A1 | ANTIVIRAL COMPOUNDS | UNIV BRIGHAM YOUNG (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2950789-A2 | ANTIVIRAL COMPOUNDS | Brigham Young University (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014121170-A2 | ANTIVIRAL COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014121170-A2 | ANTIVIRAL COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368196-A1 | ANTIVIRAL COMPOUNDS | ACE, ADA, MAVS | HSD11B1 1386/4885GRIN2D 4607/4885GRIN3B 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.